Acropolis Investment Management LLC Sells 270 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Acropolis Investment Management LLC trimmed its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 3.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,258 shares of the financial services provider’s stock after selling 270 shares during the period. Acropolis Investment Management LLC’s holdings in iShares Biotechnology ETF were worth $928,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Proficio Capital Partners LLC purchased a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth approximately $480,000. IFP Advisors Inc raised its holdings in shares of iShares Biotechnology ETF by 237.1% in the fourth quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock worth $2,118,000 after buying an additional 11,266 shares during the period. FineMark National Bank & Trust purchased a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth approximately $319,000. Destiny Wealth Partners LLC raised its holdings in shares of iShares Biotechnology ETF by 6.7% in the first quarter. Destiny Wealth Partners LLC now owns 69,865 shares of the financial services provider’s stock worth $8,936,000 after buying an additional 4,358 shares during the period. Finally, Cullen Frost Bankers Inc. raised its holdings in shares of iShares Biotechnology ETF by 1.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after buying an additional 82 shares during the period. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ IBB opened at $128.00 on Monday. The business’s 50 day moving average price is $121.95 and its 200-day moving average price is $130.33. iShares Biotechnology ETF has a fifty-two week low of $107.43 and a fifty-two week high of $150.57. The company has a market cap of $5.60 billion, a price-to-earnings ratio of 23.96 and a beta of 0.84.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.